|
2021 |
|
|
|
· Completed Phase I CordSTEM-DD(Disk Degeneration)
· Matica Biotechnology(in US) held groundbreaking ceremony for CDMO
production lines to manufacture cell and gene therapies in College Station
· Entered Australian genetic analysis market for the first time in Korea
· CHA Biolab received permission to make advanced biopharmaceutical products,
human cell management business approval, and approval of cell processing
facility
· CordSTEM-DD, POI, PD were selected as recipients of government projects |
 |
 |
· Filled IND application with MFDS for phase I/IIa study of CordSTEM®-DD
(Disk Degeneration)
· Filed IND application with MFDS for phase I study of CBT101-Solid Cancer
|
|
|
|
2020
|
|
2019 |
|
|
|
· Sang Hoon Oh appointed as new CEO
· Sold stake in US Subsidiary(Stem Cell & Regenerative Medicine International,
Inc.)
|
|
|
· JJae Hoon Song appointed as Chairman of CHA Bio Group and CHA Biotech
· Acquisition of profit-making businesses from subsidiaries and affiliate
(Businesses of Bio-based raw materials, IT service, Sales for CHA group employees)
· Jong Sung Choi appointed as Co-CEO
· Physical Division: Establishment of CHA Biolab(CMO and basic research business)
· Global phase II clinical trial for Intermittent Claudication completed
(CHA Biotech & Pluristem Therapeutics, PLX-PAD) |
|
|
|
2018
|
|
2017 |
|
|
|
· Young Wook Lee appointed as Co-CEO
· Phase I/IIa clinical trial for Stroke conducted in Korea completed(eCASs)
· Injection to patients in global phase II clinical trial for Intermittent Claudication
completed (CHA Biotech & Pluristem Therapeutics, PLX-PAD) |
|
· Injection to patients in phase I/IIa clinical trial for Stroke conducted in Korea
completed(eCASs)
· Phase I IND approval for Cartilage Defect received from MFDS in Korea(eCASs)
· Certificate of Venture Enterprise received
· Phase I/IIa IND approval for Disk Degeneration received from MFDS in Korea(eCASs) |
|
|
|
2016
|
|
|
|